Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to...